Action ESALY EISAI CO., LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Eisai Co., Ltd. OTC Markets

Actions

ESALY

US2825793092

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
FDA approves a second Alzheimer's drug that can modestly slow disease
AQ
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)
AQ
EISAI - NEW EFFICACY DATA FOR NON-CLEAR CELL RENAL CELL CARCINOMA FROM KEYNOTE-B61 ADDED TO LENVIMA US LABEL SUPPORTING KEYTRUDA + LENVIMA INDICATION FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RCC
AQ
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China
AQ
Leqembi[®] (lecanemab) launched in China
AQ
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City
AQ
Eisai : Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”
PU
BioArctic AB - FDA accepts filing of Leqembi sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease
AQ
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
AQ
FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
AQ
Eisai Named to List of The Time 100 Most Influential Companies
AQ
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform
AQ
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea
AQ
Leqembi[®] approved for the treatment of Alzheimer's disease in South Korea
AQ
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
AQ
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan
AQ
Interim Report for the period January - March 2024
AQ
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
AQ
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
AQ
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March 2025)
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 4523
  4. Action ESALY
  5. Actualités Eisai Co., Ltd.
  6. Communiqués